Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?

Pancoast tumors are a distinct and rare subset of non-small-cell lung cancers (NSCLCs). Although a trimodality approach combining induction chemoradiotherapy followed by surgery has been the standard of care over the past two decades, only a limited number of patients are eligible for this intensive treatment in routine clinical practice. Moreover, surgical procedures for Pancoast tumors often require highly specialized thoracic surgery centers.

Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial.

Background: No standard treatment exists for patients with platinum-refractory advanced type B3 thymoma and thymic carcinoma. In the PECATI trial, we sought to assess the antitumour activity and safety of lenvatinib plus pembrolizumab in this population.

Methods: In this single-arm phase 2 trial, we recruited participants from 11 hospitals in France, Italy, and Spain.

Radioimmunotherapy for lung and head and neck cancers: A comparative review of clinical trial results and sequencing strategies.

Immunotherapy has become standard of care for numerous cancer types in the past decade. Combining radiotherapy and immunotherapy has the potential to further improve outcomes by taking advantage of their theoretical synergy on antitumoral immune response. Despite promising preclinical and early clinical studies, along with significant improvements reported in specific settings, results from larger trials attempting to expand radioimmunotherapy to diverse clinical scenarios are markedly inconsistent.

Definition of resectable stage III non-small cell lung cancer: A systematic review from EORTC lung cancer group.

Background: Stage III non-small cell lung cancer (NSCLC) is a heterogenous disease requiring a multimodality treatment approach. For resectable stage III NSCLC, treatments incorporating surgery might be beneficial, however, a definition on resectable disease is lacking. The European Organization for the Treatment and Research of Cancer (EORTC) Lung Cancer Group initiative aims to provide a uniform definition of resectable stage III NSCLC.

Tight and early HbA control in patients with type 2 diabetes mellitus in Spain: quantifying the social value.

Introduction: The aim of this study was to estimate the social value of a tight and early control of patients with type 2 diabetes during the 5 years after diagnosis in Spain, compared to higher hemoglobin A1c (HbA) goals.

Methods: An economic model based on the scientific literature was used to estimate the 5-year social value of maintaining tight and early type 2 diabetes control, i.e.